Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Homa

General Practice Bridgeport, PA Doctor of Osteopathy

NPI 1316932890 CMS profile 59674

700 Dekalb St, Bridgeport, PA 19405

Open in the dashboard

General payments

$7,936

388 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Homa of Bridgeport, PA is reported in the CMS Open Payments database as having received $7,936 across 388 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $115 1
2024 General $230 2
2023 General $136 2
2022 General $154 4
2021 General $2,869 134
2020 General $1,930 114
2019 General $2,501 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Homa
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to George Homa were reported at $115. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year George Homa General Practice median Middle half National median
2019 $2,501 $107 $37–$285 $163
2020 $1,930 $75 $25–$213 $114
2021 $2,869 $93 $30–$272 $132
2022 $154 $103 $36–$279 $149
2023 $136 $106 $34–$276 $160
2024 $230 $114 $39–$290 $164
2025 $115 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $933 63 payments
  2. AstraZeneca Pharmaceuticals LP $931 43 payments
  3. Novo Nordisk Inc $692 30 payments
  4. Lilly USA, LLC $675 31 payments
  5. Merck Sharp & Dohme Corporation $507 44 payments
  6. Amarin Pharma Inc. $403 26 payments
  7. Astellas Pharma US Inc $379 17 payments
  8. GlaxoSmithKline, LLC. $301 13 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $283 15 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $239 16 payments
  11. Other $2,592 90 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,741 376 payments
  2. Education $148 10 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $655 32 payments
  2. ELIQUIS $515 36 payments
  3. Ozempic $483 23 payments
  4. STEGLATRO $446 40 payments
  5. TRULICITY $405 19 payments
  6. RYBELSUS $351 15 payments
  7. JANUVIA $332 35 payments
  8. CHANTIX $316 20 payments
  9. MYRBETRIQ $284 16 payments
  10. JARDIANCE $283 15 payments
  11. Other $6,777 375 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

388 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record